Full Text View
Tabular View
No Study Results Posted
Related Studies
The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry
This study has been completed.
Study NCT00402207   Information provided by Maastricht University Medical Center
First Received: November 20, 2006   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Asthma
More general conditions related to this trial
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Interventions listed in this trial
extrafine HFA-beclomethasone
HFA-fluticasone
Additional drug interventions recognized in this trial
Beclomethasone
Fluticasone
Nitric Oxide
More general drug interventions related to this trial
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Antioxidants
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Dermatologic Agents
Endothelium-Dependent Relaxing Factors
Free Radical Scavengers
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Maastricht University Medical Center
AstraZeneca
Teva Global Respiratory Research LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services